Source 1primary paper2023Journal of Controlled Release
Toolkit/cell membrane biomimetic core-shell system
cell membrane biomimetic core-shell system
Also known as: biomimetic gene editing system, membrane-camouflaged system
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
The cell membrane biomimetic core-shell system is a membrane-camouflaged delivery harness developed for light-controllable, precise gene editing. In the cited study, it was used as a CRISPR-Cas9 delivery strategy for tumor cell reprogramming and cancer therapy.
Usefulness & Problems
Why this is useful
This system is useful as a potential in vivo CRISPR-Cas9 delivery approach that couples biomimetic membrane camouflage with light augmentation. The reported application in H1299 cells indicates utility for tumor cell reprogramming and augmentation of antimetastatic effects.
Source:
Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Source:
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Source:
Herein, we developed a cell membrane biomimetic core-shell system for light-controllable, precise gene editing.
Problem solved
It addresses the problem of achieving precise, light-controllable gene editing with a delivery format intended for in vivo CRISPR-Cas9 use. The cited work specifically positions it as a feasible strategy for cancer therapy through tumor cell reprogramming.
Source:
Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Source:
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Source:
Herein, we developed a cell membrane biomimetic core-shell system for light-controllable, precise gene editing.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Techniques
No technique tags yet.
Target processes
editingInput: Light
Implementation Constraints
The available evidence indicates a core-shell formulation with cell membrane camouflage and light-controllable operation, and laser irradiation was used in the reported H1299 cell application. Specific membrane source, cargo formulation, irradiation parameters, and delivery protocol are not provided in the supplied evidence.
The supplied evidence is limited to a single cited study and provides little detail on construct composition, editing targets, quantitative editing efficiency, or safety. Validation explicitly described here is narrow, with reported application in H1299 cells and only a general statement of potential for in vivo delivery.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successMammalian Cell Lineapplication demoH1299 cells
Inferred from claim c4 during normalization. In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects. Derived from claim c4. Quoted text: Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Source:
successMammalian Cell Lineapplication demoH1299 cells
Inferred from claim c4 during normalization. In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects. Derived from claim c4. Quoted text: Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Source:
successMammalian Cell Lineapplication demoH1299 cells
Inferred from claim c4 during normalization. In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects. Derived from claim c4. Quoted text: Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Source:
successMammalian Cell Lineapplication demoH1299 cells
Inferred from claim c4 during normalization. In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects. Derived from claim c4. Quoted text: Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Source:
successMammalian Cell Lineapplication demoH1299 cells
Inferred from claim c4 during normalization. In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects. Derived from claim c4. Quoted text: Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Source:
successMammalian Cell Lineapplication demoH1299 cells
Inferred from claim c4 during normalization. In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects. Derived from claim c4. Quoted text: Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Source:
successMammalian Cell Lineapplication demoH1299 cells
Inferred from claim c4 during normalization. In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects. Derived from claim c4. Quoted text: Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Source:
Supporting Sources
Ranked Claims
In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
The membrane-camouflaged system combined with light augmentation provides a potential solution for in vivo delivery of CRISPR-Cas9 and a feasible strategy for cancer therapy.
Our approach of using a membrane-camouflaged system combined with light augmentation provides a potential solution for the in vivo delivery of CRISPR-Cas9 as well as a feasible strategy for cancer therapy.
The membrane-camouflaged system combined with light augmentation provides a potential solution for in vivo delivery of CRISPR-Cas9 and a feasible strategy for cancer therapy.
Our approach of using a membrane-camouflaged system combined with light augmentation provides a potential solution for the in vivo delivery of CRISPR-Cas9 as well as a feasible strategy for cancer therapy.
The membrane-camouflaged system combined with light augmentation provides a potential solution for in vivo delivery of CRISPR-Cas9 and a feasible strategy for cancer therapy.
Our approach of using a membrane-camouflaged system combined with light augmentation provides a potential solution for the in vivo delivery of CRISPR-Cas9 as well as a feasible strategy for cancer therapy.
The membrane-camouflaged system combined with light augmentation provides a potential solution for in vivo delivery of CRISPR-Cas9 and a feasible strategy for cancer therapy.
Our approach of using a membrane-camouflaged system combined with light augmentation provides a potential solution for the in vivo delivery of CRISPR-Cas9 as well as a feasible strategy for cancer therapy.
The membrane-camouflaged system combined with light augmentation provides a potential solution for in vivo delivery of CRISPR-Cas9 and a feasible strategy for cancer therapy.
Our approach of using a membrane-camouflaged system combined with light augmentation provides a potential solution for the in vivo delivery of CRISPR-Cas9 as well as a feasible strategy for cancer therapy.
The membrane-camouflaged system combined with light augmentation provides a potential solution for in vivo delivery of CRISPR-Cas9 and a feasible strategy for cancer therapy.
Our approach of using a membrane-camouflaged system combined with light augmentation provides a potential solution for the in vivo delivery of CRISPR-Cas9 as well as a feasible strategy for cancer therapy.
The membrane-camouflaged system combined with light augmentation provides a potential solution for in vivo delivery of CRISPR-Cas9 and a feasible strategy for cancer therapy.
Our approach of using a membrane-camouflaged system combined with light augmentation provides a potential solution for the in vivo delivery of CRISPR-Cas9 as well as a feasible strategy for cancer therapy.
The shell is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, producing light-controllable enhanced gene editing.
The shell of the system is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, thereby producing light-controllable enhanced gene editing.
The shell is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, producing light-controllable enhanced gene editing.
The shell of the system is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, thereby producing light-controllable enhanced gene editing.
The shell is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, producing light-controllable enhanced gene editing.
The shell of the system is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, thereby producing light-controllable enhanced gene editing.
The shell is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, producing light-controllable enhanced gene editing.
The shell of the system is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, thereby producing light-controllable enhanced gene editing.
The shell is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, producing light-controllable enhanced gene editing.
The shell of the system is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, thereby producing light-controllable enhanced gene editing.
The shell is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, producing light-controllable enhanced gene editing.
The shell of the system is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, thereby producing light-controllable enhanced gene editing.
The shell is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, producing light-controllable enhanced gene editing.
The shell of the system is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, thereby producing light-controllable enhanced gene editing.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
The authors developed a cell membrane biomimetic core-shell system for light-controllable precise gene editing.
Herein, we developed a cell membrane biomimetic core-shell system for light-controllable, precise gene editing.
The authors developed a cell membrane biomimetic core-shell system for light-controllable precise gene editing.
Herein, we developed a cell membrane biomimetic core-shell system for light-controllable, precise gene editing.
The authors developed a cell membrane biomimetic core-shell system for light-controllable precise gene editing.
Herein, we developed a cell membrane biomimetic core-shell system for light-controllable, precise gene editing.
The authors developed a cell membrane biomimetic core-shell system for light-controllable precise gene editing.
Herein, we developed a cell membrane biomimetic core-shell system for light-controllable, precise gene editing.
The authors developed a cell membrane biomimetic core-shell system for light-controllable precise gene editing.
Herein, we developed a cell membrane biomimetic core-shell system for light-controllable, precise gene editing.
The authors developed a cell membrane biomimetic core-shell system for light-controllable precise gene editing.
Herein, we developed a cell membrane biomimetic core-shell system for light-controllable, precise gene editing.
The authors developed a cell membrane biomimetic core-shell system for light-controllable precise gene editing.
Herein, we developed a cell membrane biomimetic core-shell system for light-controllable, precise gene editing.
Approval Evidence
1 source4 linked approval claimsfirst-pass slug cell-membrane-biomimetic-core-shell-system
Herein, we developed a cell membrane biomimetic core-shell system for light-controllable, precise gene editing.
Source:
application resultsupports
In H1299 cells, the biomimetic gene editing system with laser irradiation reprogrammed neoplastic cells and reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects.
Source:
delivery potentialsupports
The membrane-camouflaged system combined with light augmentation provides a potential solution for in vivo delivery of CRISPR-Cas9 and a feasible strategy for cancer therapy.
Our approach of using a membrane-camouflaged system combined with light augmentation provides a potential solution for the in vivo delivery of CRISPR-Cas9 as well as a feasible strategy for cancer therapy.
Source:
therapeutic effectsupports
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel.
Source:
tool developmentsupports
The authors developed a cell membrane biomimetic core-shell system for light-controllable precise gene editing.
Herein, we developed a cell membrane biomimetic core-shell system for light-controllable, precise gene editing.
Source:
Comparisons
Source-backed strengths
Evidence from the cited study shows that, in H1299 cells with laser irradiation, the system reprogrammed neoplastic cells and reduced VEGF and Vimentin expression. These changes were associated with enhanced antimetastatic effects, supporting functional activity in a cancer-relevant cellular context.
Ranked Citations
- 1.